| | Business Summary | | BRL
Holdings,
Inc.,
formerly
known
as
Biorelease
Corporation,
is
a
development
stage
company
engaged
in
limited
sales
of
a
proprietary,
cell-culture
additive
(Erythrogen).
The
Company
conducts
its
operations
through
its
controlled
subsidiary,
Biorelease
Technologies,
Inc.
(formerly
FLS
Acquisition
Corp.
and
doing
business
as
Biokinetics).
The
Company
introduced
its
first
cell
culture
additive,
Erythrogen,
in
late
1993.
Erythrogen
has
been
sold
to
a
number
of
research
laboratories,
including
the
NIH,
as
well
as
to
a
number
of
biotechnology
and
pharmaceutical
companies
for
incorporation
into
their
experimental
cell
culture
media.
The
Company
expects
to
continue
offering
Erythrogen
for
limited
sale
while
it
seeks
and
qualifies
one
or
several
companies
with
whom
to
merge
or
form
a
strategic
affiliation. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | BRL
Holdings,
Inc.
is
a
development
stage
company
that
holds
technology
in
the
field
of
blood
substitutes
and
sustained
release
drug
delivery
technology
based
on
chondroitin
sulfate.
For
the
nine
months
ended
3/31/01,
revenues
totaled
$14
thousand,
up
from
$4
thousand.
Net
loss
totaled
$3.8
million
vs.
an
income
of
$10
thousand.
Revenues
reflect
increased
product
revenues.
Higher
loss
reflects
increased
realized
losses
on
the
value
of
investments. | | More
from
Market Guide: Significant
Developments |
| | |
| Position | | Richard Schubert, 63 | Chairman | | R. Bruce Reeves, Ph.D., 60 | Pres,
CEO, Principal Financial Officer, Sec., Director | | Kevin McGuire, 50 | Treasurer |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/b/brln.ob.gif)